|
| Press Releases |
|
 |
|
| Thursday, June 8, 2023 |
|
|
エーザイ、抗アミロイドβプロトフィブリル抗体「レカネマブ」について、韓国において早期アルツハイマー病に係る適応で新薬承認を申請 |
| エーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫、以下 エーザイ）とバイオジェン・インク（Nasdaq：BIIB、本社：米国マサチューセッツ州ケンブリッジ、CEO：Christopher A. Viehbacher、以下 バイオジェン）は、このたび、エーザイが抗アミロイドβ（Aβ）プロト フィブリル*抗体レカネマブ（一般名、米国ブランド名：「LEQEMBI(R)」）について、脳内アミロイド病理が確認された早期アルツハイマー病（アルツハイマー病（AD）による軽度認知障害および軽度認知症）に係る適応で、韓国食品医薬品安全処（MFDS）に新薬承認申請を行いましたのでお知らせします。 more info >> |
|
| Friday, June 2, 2023 |
|
|
Eisai to Present Latest Data on Lemborexant at the 37th Annual Sleep 2023 Meeting |
| Eisai Co., Ltd. announced a total of eight poster presentations, including the latest data on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGO), will be given at the 37th annual meeting of the Associated Professional Sleep Societies (SLEEP 2023), to be held from June 3 to 7, 2023 in Indianapolis, IN, the United States. more info >> |
|
| Friday, May 26, 2023 |
|
|
LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma |
| These data will be presented on Monday, June 5 at 11:54 a.m. Central Daylight Time during an oral abstract session at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract #4502). more info >> |
|
| Thursday, May 25, 2023 |
|
|
Eisai's Initiatives for Developing New Medicines for Neglected Tropical Diseases and Malaria |
| Eisai Co., Ltd. has announced that it will grant a total of 625 million yen to the Global Health Innovative Technology Fund ("GHIT Fund") to fund the third phase of its activities, which will take place in the five-year period from FY2023 to FY2027. more info >> |
|
| Wednesday, May 24, 2023 |
|
|
Eisai Delivers New Data and Highlights Continued Progress of Oncology Portfolio and Pipeline at ASCO 2023 |
| Eisai Co., Ltd. announced today the presentation of research across various types of cancer from its oncology portfolio and pipeline during the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO23), which is taking place virtually and in-person in Chicago, Illinois from June 2 to 6. more info >> |
|
|
米国臨床腫瘍学会年次総会におけるエーザイのがん領域の製品・開発品に関する発表について |
| エーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫）は、2023年6月2日から6日まで米国イリノイ州シカゴおよびバーチャル形式で開催される「米国臨床腫瘍学会（American Society of Clinical Oncology：ASCO）年次総会」（2023 ASCO Annual Meeting）において、当社のがん領域における製品・開発品の様々ながん種における最新知見を発表することをお知らせします。 more info >> |
|
| Saturday, May 20, 2023 |
|
|
Eisai Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease in Great Britain |
| Eisai Co., Ltd. and Biogen Inc. announced today that Eisai has submitted a Marketing Authorization Application (MAA) for lecanemab, an investigational anti-amyloid beta (Aβ) protofibril antibody, for the treatment of early Alzheimer's disease (mild cognitive impairment due to Alzheimer's disease (AD) and mild AD dementia) with confirmed amyloid pathology in the brain, to the UK Medicines and Healthcare products Regulatory Agency (MHRA) in Great Britain. more info >> |
|
| Monday, May 22, 2023 |
|
|
エーザイ、抗アミロイドβプロトフィブリル抗体「レカネマブ」について、英国（北アイルランドを除く）において早期アルツハイマー病に係る販売承認申請を提出 |
| エーザイ株式会社とバイオジェン・インクは、このたび、英国（北アイルランドを除く）において、 エーザイが抗アミロイドβ（Aβ）プロトフィブリル抗体レカネマブ（一般名）について、脳内 アミロイド病理が確認された早期アルツハイマー病（アルツハイマー病（AD）による軽度認知障害および軽度認知症）に係る販売承認申請（MAA）を、英国医薬品医療製品規制庁（MHRA）に提出したことをお知らせします。 more info >> |
|
| Wednesday, May 17, 2023 |
|
|
エーザイ、臨床第III相Clarity AD試験データを用いた、日本における「レカネマブ」の社会的価値について、査読学術専門誌Neurology and Therapy誌に掲載 |
| エーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫）は、このたび、アルツハイマー病（AD）による軽度認知障害（MCI）および軽度AD（総称して早期ADと定義）当事者様に対する抗アミロイドβ（Aβ）プロトフィブリル*抗体レカネマブ（一般名、米国ブランド名「LEQEMBITM」）の日本の医療システム下における社会的価値をシミュレーションした結果が査読学術専門誌Neurology and Therapy誌に掲載されたことをお知らせします。 more info >> |
|
| Tuesday, May 16, 2023 |
|
|
Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer's Disease |
| Eisai Co., Ltd. and Biogen Inc. announced today that Health Canada has accepted a New Drug Submission (NDS) for lecanemab (brand name in the U.S.: LEQEMBI), an investigational anti-amyloid beta (Abeta) protofibril* antibody, for the treatment of early Alzheimer's disease (mild cognitive impairment due to Alzheimer's disease (AD) and mild AD dementia) with confirmed amyloid pathology in the brain. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Geon Performance Solutions Updates Brand Identity to Reflect Expanded Capabilities in Polymer Industry
Jan 23, 2026 15:16 HKT/SGT
|
|
|
Honda、大型アドベンチャーモデル「CRF1100L Africa Twin Adventure Sports ES Dual Clutch Transmission」のカラーリングを変更し発売
Jan 23, 2026 12:20: JST
|
|
|
HKTDC and Microsoft Hong Kong jointly launch the Microsoft AI Adoption Programme Helping SMEs boost productivity through AI and accelerate digital transformation
Jan 23, 2026 11:54 HKT/SGT
|
|
|
Geon Performance Solutions更新品牌識別，彰顯聚合物產業擴展實力
Jan 23, 2026 07:00 HKT/SGT
|
|
|
Geon高性能解决方案更新品牌形象，彰显聚合物行业拓展实力
Jan 23, 2026 07:00 HKT/SGT
|
|
|
Open World Launches Saudi Arabia's First RWA Tokenization Center of Excellence to Advance Vision 2030 Digital Economy Goals
Jan 22, 2026 22:14: JST
|
|
|
Davos Highlights Physical AI as Key Trend, 51 WORLD (6651.HK) Emerges as Industry Implementer
Jan 22, 2026 20:13 HKT/SGT
|
|
|
Open World Launches Saudi Arabia's First RWA Tokenization Center of Excellence to Advance Vision 2030 Digital Economy Goals
Jan 22, 2026 20:00 HKT/SGT
|
|
|
The 35th Education & Careers Expo opens today
Jan 22, 2026 18:00 HKT/SGT
|
|
|
向「數」而生 由「智」而行：中國數智科技全面開啟Web3.0全生態佈局
Jan 22, 2026 11:56 HKT/SGT
|
|
|
向"数"而生 由"智"而行：中国数智科技全面开启Web3.0全生态布局
Jan 22, 2026 11:56 HKT/SGT
|
|
|
龍旗科技今日登陸港交所：強大基石陣容 端側AI龍頭龍旗邁入全球化發展新紀元
Jan 22, 2026 11:38 HKT/SGT
|
|
|
龙旗科技今日登陆港交所：强大基石阵容 端侧AI龙头龙旗迈入全球化发展新纪元
Jan 22, 2026 11:38 HKT/SGT
|
|
|
みずほ銀行と富士通、受発注・決済領域における中堅・中小企業向け新サービス創出に向けた企画・開発を開始
Jan 22, 2026 11:30: JST
|
|
|
華營控股榮膺「香港義工獎2025」雙項殊榮 實踐企業責任 共建關愛香港
Jan 22, 2026 11:00 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
